Real-World Outcomes With Generic Pomalidomide in Relapsed Refractory Multiple Myeloma—Experience From a Tertiary Care Cancer Center

PURPOSE: The prognosis of relapsed and refractory multiple myeloma (RRMM) that is refractory to bortezomib and lenalidomide is very poor wherein the median survival is between 3 and 9 months. We did this retrospective analysis to study the pattern of utilization, tolerance, and outcomes with pomalid...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCO Glob Oncol
Main Authors: Bondili, Suresh Kumar, Bagal, Bhausaheb, Zawar, Abhinav, Ventrapati, Pradeep, Thorat, Jayashree, Gokarn, Anant, Punatar, Sachin, Nayak, Lingaraj, Bonda, Avinash, Jain, Hashmukh, Sengar, Manju, Khattry, Navin
Formato: Artigo
Idioma:Inglês
Publicado em: Wolters Kluwer Health 2021
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8081531/
https://ncbi.nlm.nih.gov/pubmed/33689483
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/GO.20.00228
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados